Summary & Overview
CPT 80347: Benzodiazepine Panel, 13+ Analytes
CPT code 80347 denotes a clinical laboratory toxicology assay that detects or quantifies 13 or more benzodiazepines in a patient specimen. This code covers high-complexity multi-analyte benzodiazepine testing used in clinical, emergency, and forensic contexts to inform acute care, medication management, and compliance monitoring. Nationally, accurate coding of multi-drug toxicology panels matters for consistent clinical documentation, appropriate claims processing, and population-level surveillance of sedative-hypnotic exposure.
Key payers in the coverage landscape include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find benchmarks for code utilization, payer coverage patterns, and clinical context for when multi-analyte benzodiazepine testing is used. The publication outlines coding considerations, typical sites of service, and operational notes relevant to laboratories and billing teams. It also summarizes implications for utilization review and reimbursement policy, and highlights common clinical scenarios that prompt ordering of a 13+-analyte benzodiazepine panel. Data not available in the input for specific payer policies, fee schedules, or utilization metrics is noted where applicable.
Billing Code Overview
CPT code 80347 reports laboratory testing that measures the amount of, or detects the presence of, 13 or more benzodiazepines (tranquilizers) in a patient specimen. The test is a multi-analyte toxicology screen designed to identify benzodiazepine class drugs and their metabolites.
-
Service type: Clinical laboratory toxicology screening for benzodiazepines
-
Typical site of service: Clinical laboratory or hospital laboratory; specimens are commonly collected in outpatient clinics, emergency departments, or inpatient settings depending on clinical need.
Clinical & Coding Specifications
Clinical Context
A 38-year-old patient presents to an emergency department after a motor vehicle collision with altered mental status and a history of chronic benzodiazepine use for anxiety. The treating team orders comprehensive toxicology testing to guide acute management, medication reconciliation, and potential adverse interaction identification. A blood or urine specimen is collected and sent to the clinical laboratory. The laboratory performs a multi-analyte benzodiazepine screen using mass spectrometry or immunoassay panels configured to measure or detect 13 or more benzodiazepine compounds and metabolites. Results are reported to the ordering clinician and documented in the electronic medical record to support decisions about sedation reversal, antidotal therapies, admission level of care, and forensic or occupational health documentation when applicable.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Default/No modifier specified | Rarely appended; indicates standard reporting when no other modifier applies. |
22 | Increased procedural services | Use when unusually complex laboratory procedures significantly increase work and resources beyond typical testing.
26 | Professional component | Use when billing only the professional component (interpretation or reporting) separated from technical services.